PEX7: A Potential Drug Target and Biomarker for Peroxisomal Targeting Signal 2 Receptor

Target Name: PEX7

NCBI ID: G5191

PEX7

PEX7: A Potential Drug Target and Biomarker for Peroxisomal Targeting Signal 2 Receptor

Abstract: Peroxisomal targeting signal 2 (PTS2) is a G protein-coupled receptor that plays a crucial role in the regulation of cellular processes, including cell growth, differentiation, and survival. PEX7, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for PTS2 receptor. This article reviews the current understanding of PEX7 and its potential implications as a drug target and biomarker.

Introduction: Peroxisomes are organelles responsible for the biosynthesis and storage of various molecules, including toxins and neurotransmitters. Peroxisomal disorders are a group of genetic disorders caused by defects in peroxisomal proteins, which are involved in the regulation of peroxisomal processes. The PTS2 receptor, a G protein-coupled receptor, is a key regulator of peroxisomal function. Activation of the PTS2 receptor leads to various cellular responses, including the inhibition of peroxisomal enzymes and the production of pro-inflammatory cytokines.

Recent studies have identified PEX7 as a potential drug target and biomarker for PTS2 receptor. PEX7 is a non-coding RNA molecule that is expressed in various tissues and cells, including peroxisomes, neurons, and cancer cells. PEX7 has been shown to play a role in the regulation of peroxisomal processes, including the regulation of peroxisomal enzymes and the modulation of cellular signaling pathways.

Potential Drug Target: PEX7 can be potential drug target for PTS2 receptor due to its unique structure and biological activity. PEX7 is a non-coding RNA molecule whose coding gene is located on the X chromosome. About 20% of human genetic diseases are related to chromosomal abnormalities. In addition, PEX7 has unique biological activities that can activate or inhibit a variety of intracellular signaling pathways, thereby potentially becoming a promising drug target.

Biomarker: PEX7 can be used as a biomarker for PTS2 receptor. Some studies have shown that PEX7 expression levels can serve as an indicator of PTS2 receptor function. In addition, PEX7 can also be used to detect the function of the PTS2 receptor, for example, by using PEX7 knockout mice to evaluate its effect on the PTS2 receptor.

Conclusion: In conclusion, PEX7 is a potential drug target and biomarker for PTS2 receptor due to its unique structure and biological activity. Further research is needed to fully understand the role of PEX7 in peroxisomal processes and its potential as a drug.

Protein Name: Peroxisomal Biogenesis Factor 7

Functions: Receptor required for the peroxisomal import of proteins containing a C-terminal PTS2-type peroxisomal targeting signal (PubMed:9090381, PubMed:11931631, PubMed:22057399, PubMed:25538232). Specifically binds to cargo proteins containing a PTS2 peroxisomal targeting signal in the cytosol (PubMed:11931631, PubMed:22057399, PubMed:25538232). Cargo protein-binding triggers interaction with PEX5 and formation of a ternary complex composed of PEX5 and PEX7 along with PTS2-containing cargo proteins, which is tranlocated into peroxisomes by passing through the PEX13-PEX14 docking complex (PubMed:11546814, PubMed:25538232)

The "PEX7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEX7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets